Leonard M. Miller School of Medicine

Specific Biologics Announces Additional Investment and Appointment of Experienced Biotechnology Leader Steven Kanner, PhD, to the Board of Directors

Retrieved on: 
화요일, 10월 10, 2023
ADMAR, Cystic Fibrosis Foundation, MBA, Doctor of Philosophy, Research, Pregnancy specific biological substances, G.H. Raisoni Department of Microbiology and Biotechnology, Bristol Myers Squibb, Berkeley, MD, Master of Science, Organization, Therapy, Liver, Genetics, University, Mutation, Rachel Haurwitz, Disease, University of Miami Division of Surgical Neurooncology, Arrowhead Pharmaceuticals, Leonard M. Miller School of Medicine, Cystic fibrosis, Annual Review of Cancer Biology, University of Virginia Cancer Center, Acute leukemia, DSM-IV codes, Gene editing, Astex Pharmaceuticals, Specific, Dasatinib, CNS, Patient, Vaccine, Pharmaceutical industry, Investment, Microbiology, Immunology

Specific Biologics is an early-stage biotechnology company developing its proprietary two-site Dualase® platform gene editors to build a pipeline of treatments for serious genetic diseases.

Key Points: 
  • Specific Biologics is an early-stage biotechnology company developing its proprietary two-site Dualase® platform gene editors to build a pipeline of treatments for serious genetic diseases.
  • TORONTO, Oct. 10, 2023 /PRNewswire/ - Specific Biologics Inc. ("Specific"), a venture-backed, early-stage genome editing company, is pleased to announce it has appointed Steven Kanner, PhD, as an Independent Director.
  • The appointment coincides with renewed investment from Lumira Ventures and adMare BioInnovations to advance the preclinical development of therapeutics based on Specific's proprietary Dualase® platform gene editors.
  • The additional investment from Lumira Ventures and adMare BioInnovations will be used to advance preclinical testing of Dualase gene editors in liver, ocular and CNS disorders.

ZyVersa Therapeutics Announces New Peer-Reviewed Publication Reinforcing the Rationale for Inhibiting ASC Specks with IC 100 to Attenuate Spread of Inflammation into Surrounding Tissues

Retrieved on: 
수요일, 10월 4, 2023
Heart, ASC, Tissue, MEFV, University, Microbiology, Inflammasome, Leonard M. Miller School of Medicine, AIM2, Serum, Associate professor, Neurosurgery, Traumatic brain injury, Bacterial conjugation, Brain, TBI, Inflammation, Research, CNS, EVS, Super Meat Boy, Seminal vesicles, Journal, Patient, Translational research, Invention, Mouse, Paper, Immunology, Therapy, Injury, Physiology, Pharmaceutical industry, Vaccine, Medication, Biophysics, Medicine

Marks the third publication in 2023 supporting the potential need to attenuate the spread of inflammation to surrounding tissues to minimize the potential for co-morbidities in certain diseases.

Key Points: 
  • Marks the third publication in 2023 supporting the potential need to attenuate the spread of inflammation to surrounding tissues to minimize the potential for co-morbidities in certain diseases.
  • ZyVersa is developing Inflammasome ASC Inhibitor IC 100 to inhibit multiple types of inflammasomes and their associated ASC specks that trigger damaging inflammation and its spread to surrounding tissues.
  • Data indicate that pyrin inflammasome-mediated inflammation induced by TBI contributes to cardiovascular co-morbidities through systemic release of proinflammatory mediators that activate AIM2 inflammasomes in the heart leading to damaging inflammation.
  • “A heightened systemic inflammatory response is often induced after TBI, but the underlying pathomechanisms that contribute to co-morbidities remain poorly understood.

Precision Medicine and Alzheimer's Disease: Overcoming Biomarker Testing Barriers for Alzheimer's Disease Patients, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
수요일, 9월 13, 2023
AIM, University, Leonard M. Miller School of Medicine, Personalized medicine, DSM-IV codes, Biomarker, MCI, Doctor of Philosophy, DMTS, Patient, Psychiatry, Behavioural sciences, Neurology, Alzheimer's disease, Nursing, Medical imaging

TORONTO, Sept. 13, 2023 /PRNewswire-PRWeb/ -- Advances in biomarker testing are revolutionizing strategies for diagnosing and managing neurological disorders and shifting the current treatment paradigm to a more personalized approach.

Key Points: 
  • The featured speakers will review key barriers to clinical adoption of MCI and early AD-related biomarker testing.
  • Learn about what steps can be taken to overcome these testing barriers and optimize availability and access to testing.
  • This expert panel featuring Pete Riccelli, PhD, Senior Director, Precision Medicine, Commercial Strategy and Market Access, Veranex ; Catheline Plaideau, PhD, Sr.
  • Register for the live webinar taking place on Tuesday, October 3, 2023, at 12pm EDT (11am CDT) to learn how to identify and overcome challenges in Alzheimer's disease biomarker testing.

Couple gives back with gratitude

Retrieved on: 
수요일, 9월 6, 2023
University, College, Campaign, Silver, Leonard M. Miller School of Medicine, Woman, Tropical cyclone, Orange Bowl, Team, Bowl game, College of Arts and Sciences (Case Western Reserve University), Century, Science, CORAL, Miami Hurricanes, Female, Nursing

Looking back, they marvel at the countless ways, large and small, that the University made a meaningful difference in their lives.

Key Points: 
  • Looking back, they marvel at the countless ways, large and small, that the University made a meaningful difference in their lives.
  • “Dean Brunson was a lifesaver,” declared Patricia, who earned her Bachelor of Science degree in 1969.
  • So, when they contemplated a more substantial legacy, they decided to make an estate gift to Hurricane Athletics.
  • The Cases’ bequest will support the areas of greatest need in athletics, be they scholarships, support programs for student-athletes, facilities improvements, or related needs.

STAT to host three-day, virtual 'Future Summit' September 5-7

Retrieved on: 
목요일, 8월 31, 2023
Rachel Haurwitz, UC Davis School of Medicine, Indigenous health in Australia, University, Internal medicine, Leonard M. Miller School of Medicine, Public, Health equity, Cancer, Bristol Myers Squibb, Research, STAT, Vanderbilt University Medical Center, AstraZeneca, Health policy, Associate, Science, Thought, Interest, Assistant, Amazon, Global Health, US, Public health, Johns Hopkins University, UC, Johns Hopkins Bloomberg School of Public Health, School, Outreach, Purdue University, McGill University, Health, MPH, SVP, Surgeon General of the United States, International health, Management, Sport, Pharmaceutical industry, Medicine

BOSTON, Aug. 31, 2023 /PRNewswire/ -- STAT, the leading media company reporting on health, science, and medicine, is proud to host its inaugural STAT Future Summit next week, Sept. 5-7. The three-day, virtual event will focus on one key theme each day — the future of medicine, the future of cancer, and the future of health care. Programming will run from 12 p.m. to 3 p.m. ET each day. Attendees will also have the option to access session recordings on demand, about 24 hours after a session concludes. Interested media can email Brittany Cipriano, senior director of events at STAT, at [email protected] to register for the event.

Key Points: 
  • The 2023 STAT Future Summit features conversations with thought leaders paving the way to a new era of medicine.
  • BOSTON, Aug. 31, 2023 /PRNewswire/ -- STAT , the leading media company reporting on health, science, and medicine, is proud to host its inaugural STAT Future Summit next week, Sept. 5-7.
  • The three-day, virtual event will focus on one key theme each day — the future of medicine, the future of cancer, and the future of health care.
  • Interested media can email Brittany Cipriano, senior director of events at STAT, at [email protected] to register for the event.

ZyVersa Therapeutics Publishes New White Paper Detailing the Critical Role of Inflammasome ASC in Inflammatory Diseases, and Its Potential as a Therapeutic Target

Retrieved on: 
화요일, 6월 13, 2023
GMP, ASC, University, Diabetes, Leonard M. Miller School of Medicine, The Michael J. Fox Foundation, Cancer, World Health Organization, Research, Inflammation, Cell, Multiple sclerosis, Inflammasome, Patient, Respiratory failure, Traumatic brain injury, Soft tissue injury, Mouse, Acute respiratory distress syndrome, Health, Therapy, Death, Safety, IND, Medicine, Injury, Pharmaceutical industry, DRS

Data suggest that drugs targeting ASC may provide the best opportunity to control damaging inflammation associated with diseases affecting millions of people worldwide.

Key Points: 
  • Data suggest that drugs targeting ASC may provide the best opportunity to control damaging inflammation associated with diseases affecting millions of people worldwide.
  • The white paper titled, “Inflammasome ASC: A Promising Therapeutic Target,” can be accessed by Clicking Here .
  • Fox Foundation.”
    “ZyVersa, which obtained a worldwide license for Inflammasome ASC Inhibitor IC 100, is honored to collaborate with Drs.
  • We are excited about our progress, as we believe Inflammasome ASC Inhibitor IC 100 has potential to transform treatment of debilitating inflammatory diseases.”

Arrowhead Hosts R&D Day Highlighting Its Pipeline of RNAi Therapeutics

Retrieved on: 
목요일, 6월 1, 2023
Research, Genetics, Clinical Trials, Biotechnology, Managed Care, Health, Pharmaceutical, General Health, Science, Molecule, Arrowhead, Idiopathic pulmonary fibrosis, Asthma, Research and development, University, Therapy, Hypertriglyceridemia, File, Leonard M. Miller School of Medicine, Serum, CTA, Targeted molecular therapy for neuroblastoma, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., NYU Langone Health, CNS, Hepatocyte, University of Kansas Medical Center, Small RNA, SOD1, Arrowhead Pharmaceuticals, Patient, Primate, Fatty liver disease, Liver, RNA interference, ASCVD, Adipose tissue, Moyamoya disease, R, Goldberg, ALS, Gene, Medical device, Pharmaceutical industry

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) is hosting a Research & Development (R&D) Day today beginning at 9:00 a.m.

Key Points: 
  • Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) is hosting a Research & Development (R&D) Day today beginning at 9:00 a.m.
  • ET to discuss progress towards the company’s “20 in 25” goal to grow its pipeline of RNAi therapeutics that leverage the proprietary Targeted RNAi Molecule (TRiM™) platform to a total of 20 clinical stage or marketed products in the year 2025.
  • Christopher Anzalone, Ph.D., President and CEO at Arrowhead, said: “In 2017 we had optimized the TRiM™ platform for hepatocyte delivery, but we had yet to advance any candidates into clinical studies.
  • (University of Kansas Medical Center), who will discuss the muco-obstructive and inflammatory pulmonary disease landscape; and Ira Goldberg, M.D.

The Society of Interventional Radiology hosts Men's Health Month briefing to raise awareness of cutting-edge treatments

Retrieved on: 
수요일, 5월 31, 2023
PAE, Society, University, Capitol Hill, Society of Interventional Radiology, Health, Leonard M. Miller School of Medicine, Prostatic artery embolization, MBA, Artery, Prostate, Interventional radiology, Patient, Urinary retention, 2019 USA Team Handball College Nationals - Men's Division, Knowledge, Capitol, System, Cannon House Office Building, Medical imaging, Pharmaceutical industry, Urology

FAIRFAX, Va., May 31, 2023 /PRNewswire/ -- The Society of Interventional Radiology will host a Capitol Hill briefing on prostate health on June 5, highlighting a state-of-the-art, minimally-invasive procedure known as prostate artery embolization (PAE).

Key Points: 
  • FAIRFAX, Va., May 31, 2023 /PRNewswire/ -- The Society of Interventional Radiology will host a Capitol Hill briefing on prostate health on June 5, highlighting a state-of-the-art, minimally-invasive procedure known as prostate artery embolization (PAE).
  • With PAE, interventional radiologists inject tiny particles into arteries that feed the prostate gland, reducing its blood supply, thereby shrinking it.
  • "The biggest barrier to treatments like prostate artery embolization is public awareness," said Alda L. Tam, M.D., MBA, FSIR, FACR, President of the Society of Interventional Radiology and Professor at the University of Texas M.D.
  • The briefing will take place on June 5, at 1 p.m. in room 401 at the Cannon House Office Building.

Muscular Dystrophy Association Tribute Awards in Washington D.C. Honor Diana X. Bharucha-Goebel, M.D., R. Rodney Howell, M.D., Paul Robertson, Jeni Stepanek, Ph.D., Janet Woodcock, M.D.

Retrieved on: 
목요일, 5월 11, 2023
Commissioner, Volunteering, Heart, John P. Hussman Institute for Human Genomics, University, Education, Life, Muscular Dystrophy Association, Associate professor, Muscular dystrophy, Genomics, Quality of life, Hope, Food and Drug Administration, Research, Leonard M. Miller School of Medicine, University of Miami, Science, National Press Club (United States), The National, Children's National Hospital, Neuromuscular disease, Professor, Patient, Neurology, Health, MDA, ALS, Food, Pharmaceutical industry, Pediatrics, D.C

The MDA Tribute Award recipients have all contributed to significant progress in accelerating research, advancing care, and advocating for the support of people living with neuromuscular diseases.

Key Points: 
  • The MDA Tribute Award recipients have all contributed to significant progress in accelerating research, advancing care, and advocating for the support of people living with neuromuscular diseases.
  • The MDA Tribute Awards presentation and reception will be held on Saturday, June 3, 2023, from 6-8:30pm at The National Press Club.
  • They are presented to acknowledge the legacy and life's work of those whose extraordinary efforts support the patients and families MDA serves.
  • The MDA legacy represents the contributions of so many pioneers who, through their work, have changed the trajectory for neuromuscular disease.

Arrowhead Pharmaceuticals to Host R&D Day on Pipeline of RNAi Therapeutics

Retrieved on: 
수요일, 4월 12, 2023
Cardiology, Biotechnology, Other Health, Health, General Health, Pharmaceutical, Medical Devices, Research, Genetics, Science, Clinical Trials, Molecule, Arrowhead, Rat, Research and development, Central nervous system, Asthma, University, Therapy, Hypertriglyceridemia, File, Leonard M. Miller School of Medicine, CTA, Targeted molecular therapy for neuroblastoma, Brain, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., NYU Langone Health, CNS, University of Kansas Medical Center, SOD1, Arrowhead Pharmaceuticals, Patient, Primate, Fatty liver disease, RNA interference, Moyamoya disease, R, Benatar, ALS, Vaccine, Pharmaceutical industry, ASCVD

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a Research & Development (R&D) Day on June 1, 2023, beginning at 9 a.m.

Key Points: 
  • Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a Research & Development (R&D) Day on June 1, 2023, beginning at 9 a.m.
  • ET in New York City to discuss progress towards the company’s “20 in 25” goal to grow its pipeline of RNAi therapeutics that leverage the proprietary Targeted RNAi Molecule (TRiMTM) platform to a total of 20 clinical stage or marketed products in the year 2025.
  • The R&D Day will feature presentations by three key opinion leaders: Ira Goldberg, M.D.
  • A copy of the presentation materials and webcast links may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.